1. Home
  2. Search

Search

Search results

373 results found

Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.

Publication: Journal Article
Comella, CL, J Jankovic, RA Hauser, AT Patel, MD Banach, E Ehler, D Vitarella, RG Rubio, and TM Gross. 2024. “Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.”. Neurology. 2024 Feb 27;102(4):e208091. Doi: 10.1212/WNL.0000000000208091. Epub 2024 Jan 31. PMID: 38295339.

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia. 2022 Oct 20;13:846126. doi: 10.3389/fneur.2022.846126. eCollection 2022. PMID: 36341088

Publication: Journal Article
Pahwa, R, S Fox, RA Hauser, S Isaacson, J Lytle, R Johnson, L Llorens, AE Formella, and CM Tanner. 2022. “Clinically Important Change on the Unified Dyskinesia Rating Scale Among Patients With Parkinson’s Disease Experiencing Dyskinesia. 2022 Oct 20;13:846126. Doi: 10.3389/Fneur.2022.846126. ECollection 2022. PMID: 36341088”. Front Neurol.

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. 2022 Dec;21(12):1099-1109. doi: 10.. PMID: 36402160

Publication: Journal Article
Soileau, MJ, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, et al. 2022. “Safety and Efficacy of Continuous Subcutaneous Foslevodopa-Foscarbidopa in Patients With Advanced Parkinson’s Disease: a Randomised, Double-Blind, Active-Controlled, Phase 3 Trial. 2022 Dec;21(12):1099-1109. Doi: 10. PMID: 36402160”. Lancet Neurol.

Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.

Publication: Journal Article
Simuni, T, B Fiske, K Merchant, CS Coffey, E Klingner, C Caspell-Garcia, DE Lafontant, et al. 2021. “Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.”. JAMA Neurol.

Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. NPJ Parkinsons Dis 2021;7:34. doi: 10.1038/s41531-021-00177-8.PMID: 33846349

Publication: Journal Article
Naito, A, AM Wills, TF Tropea, A Ramirez-Zamora, RA Hauser, D Martino, TH Turner, and . 2021. “Expediting Telehealth Use in Clinical Research Studies: Recommendations for Overcoming Barriers in North America. NPJ Parkinsons Dis 2021;7:34. Doi: 10.1038/S41531-021-00177-8.PMID: 33846349”. NP J Parkinsons Dis.

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. doi: 10.1007/s40120-021-00246-3

Publication: Journal Article
Mehta, SH, R Pahwa, CM Tanner, RA Hauser, and R Johnson. 2021. “Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. Doi: 10.1007/S40120-021-00246-3”. Neurol Ther.

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. doi: 10.1002/mds.28702. Epub 2021 Jun 30. PMID: 34191352.

Publication: Journal Article
Videnovic, A, AW Amara, C Comella, PK Schweitzer, H Emsellem, K Liu, AL Sterkel, et al. 2021. “Solriamfetol for Excessive Daytime Sleepiness in Parkinson’s Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. Doi: 10.1002/Mds.28702. Epub 2021 Jun 30. PMID: 34191352.”. Mov Disord.